Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
(4) - EconoTimes)
WAYNE, Pa., May 02, 2018 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that on May 1, 2018 the Compensation Committee of Aclaris’ Board of Directors granted 3 non-qualified stock option awards to purchase an aggregate of 21,000 shares of its common stock and 8 restricted stock unit awards covering an aggregate of 17,000 shares of its common stock to 8 new employees under the Aclaris 2017 Inducement Plan. The stock options and restricted stock units were granted as inducements material to the new employees becoming employees of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4).
The 2017 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aclaris (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Aclaris, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
The options have an exercise price of $18.07 per share, which is equal to the closing price of Aclaris' common stock on May 1, 2018. Each option and restricted stock unit award will vest, and become exercisable (as applicable), as to twenty-five percent of the shares on each of the first, second, third and fourth anniversaries of the recipient's start date, subject to each such employee's continued employment with Aclaris on such vesting dates. The options and restricted stock unit awards are subject to the terms and conditions of Aclaris' 2017 Inducement Plan, and the terms and conditions of a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology. Aclaris’ focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts, alopecia areata, and vitiligo. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
Aclaris Contact
Michael Tung, M.D.
Senior Vice President
Corporate Strategy/Investor Relations
484-329-2140
[email protected]
